Johnson & Johnson Announces 64th Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 3.1%
Johnson & Johnson Showcases New Clinical Data for TECNIS PureSee IOL at ASCRS 2026 Demonstrating Excellent Contrast Sensitivity and Extended Range of Vision
Johnson & Johnson Advances Pulsed Field Ablation Portfolio with the Launch of VARIPULSE Pro in Europe
Johnson & Johnson Advances Pulsed Field Ablation Portfolio with the Launch of VARIPULSE Pro in Europe
ICOTYDE one-year results confirm lasting skin clearance and favorable safety profile in once?daily pill for plaque psoriasis
FDA approval of ICOTYDE ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide
Johnson & Johnson highlights promising first-in-human Erda-iDRS results in intermediate-risk non-muscle-invasive bladder cancer
Johnson & Johnson Announces FDA Approval of TECNIS PureSee Intraocular Lens, a Breakthrough Solution for U.S. Cataract Patients
Johnson & Johnson therapy nipocalimab granted U.S. FDA Fast Track designation in systemic lupus erythematosus
Early study results from Johnson & Johnson show promising antitumor activity with combination of pasritamig and docetaxel in advanced prostate cancer
Johnson & Johnson seeks FDA approval of IMAAVY® as the first-ever FDA-approved treatment for warm autoimmune hemolytic anemia
TREMFYA® long-term data show sustained clinical and endoscopic remission in ulcerative colitis through 3 years
SAGA Metals Signs Definitive Agreement to Acquire Wolverine Heavy Rare Earth Element Project in Labrador-Mineralized Potential Similar to Strange Lake and Tanbreez
